Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

BioHarvest Sciences – Growing Exponentially

BioHarvest Sciences (CSNX: BHSC) is a rising star in the food, nutraceutical and cannabis industries. Through its intellectual property, it has developed a shortcut that could lead to cost savings and larger gross margins for its partners and future clients as well as a ...
Dr. Kal Kotecha | October 2, 2020 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences

Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. Clin...
Streetwise Reports | June 12, 2020 |

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Co

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary Source: Gail Dutton of The Life Sciences Report (12/22/15) https://www.thelifesciencesreport.com/pub/na/aethlon-medical...
Gail Dutton | December 23, 2015 |

Buzz on the Bullboards: Crisis Creates Opportunity

As November draws to a close, many investors may take time to consider what they are thankful for. Even if the American Thanksgiving isn’t something you celebrate, there are a lot of reasons to be thankful these days, from having our health, to major stock...
Stockhouse Editorial | November 25, 2020 |

HAVN Life Sciences: a biotech company developing technology-focused, data-driven psychedelic therapi

HAVN Life Sciences is a biotech company focused on psychedelic therapies. The Vancouver-based company develops technology-focused, data-driven, and medical-based solutions. Joining us here at the Top Line today is HAVN Life Sciences CEO, Tim Moore. Welcome back a...
Simon Druker | March 30, 2023 |

Critical Cesium Supply Is Sold to China

A Monday Morning Musing from Mickey the Mercenary Geologist Contact@MercenaryGeologist.com July 1, 2019 Little more than two months ago, I reported on the pending sale of America’s world monopoly in cesium, a Trump Administration-designated critical...
Michael S. (Mickey) Fulp | July 11, 2019 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |
1 2 3 4 5 6 7 8 9 10 ...